SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
---|---|---|---|---|---|---|---|---|---|
18-Nov-24 4:20 PM View: | Ebsworth David R Director | Verona Pharma Plc (VRNA) | 18-Nov-24 | Private Purchase | 20,000 | $4.44 | $88,800.00 | 2% 920.0K to 940.0K | |
13-Sep-24 4:15 PM View: | Zaccardelli David President and CEO Director | Verona Pharma Plc (VRNA) | 11-Sep-24 | Sale (Planned) | 600,000 | $3.76 | $2,254,320.00 | (4%) 15.85M to 15.25M | |
13-Sep-24 4:15 PM View: | Hahn Mark W Chief Financial Officer | Verona Pharma Plc (VRNA) | 11-Sep-24 | Sale (Planned) | 600,000 | $3.76 | $2,254,080.00 | (4%) 14.94M to 14.34M | |
14-Aug-24 4:16 PM View: | Zaccardelli David President and CEO Director | Verona Pharma Plc (VRNA) | 13-Aug-24 | Sale (Planned) | 398,400 | $3.20 | $1,275,680.00 | (2%) 16.25M to 15.85M | |
14-Aug-24 4:15 PM View: | Hahn Mark W Chief Financial Officer | Verona Pharma Plc (VRNA) | 13-Aug-24 | Sale (Planned) | 398,400 | $3.20 | $1,275,540.00 | (3%) 15.34M to 14.94M | |
14-Aug-24 4:15 PM View: | Ebsworth David R Director | Verona Pharma Plc (VRNA) | 12-Aug-24 | Private Purchase | 36,000 | $2.87 | $103,320.00 | 4% 844.64K to 880.64K | |
14-Aug-24 4:15 PM View: | Hahn Mark W Chief Financial Officer | Verona Pharma Plc (VRNA) | 12-Aug-24 | Sale (Planned) | 1,600 | $3.13 | $5,008.00 | (< 1%) 15.34M to 15.34M | |
14-Aug-24 4:16 PM View: | Zaccardelli David President and CEO Director | Verona Pharma Plc (VRNA) | 12-Aug-24 | Sale (Planned) | 1,600 | $3.13 | $5,008.00 | (< 1%) 16.25M to 16.25M | |
09-Aug-24 7:12 PM View: | Rickard Kathleen A. Chief Medical Officer | Verona Pharma Plc (VRNA) | 07-Aug-24 | Payment of Exercise | 87,904 | $2.62 | $230,308.00 | (3%) 2.72M to 2.63M | |
09-Aug-24 7:13 PM View: | Zaccardelli David President and CEO Director | Verona Pharma Plc (VRNA) | 07-Aug-24 | Payment of Exercise | 314,800 | $2.62 | $824,776.00 | (2%) 16.57M to 16.25M | |
09-Aug-24 7:11 PM View: | Hahn Mark W Chief Financial Officer | Verona Pharma Plc (VRNA) | 07-Aug-24 | Grant | 800,000 | -- | -- | 5% 14.85M to 15.65M | |
09-Aug-24 7:12 PM View: | Rickard Kathleen A. Chief Medical Officer | Verona Pharma Plc (VRNA) | 07-Aug-24 | Grant | 200,000 | -- | -- | 8% 2.52M to 2.72M | |
09-Aug-24 7:13 PM View: | Zaccardelli David President and CEO Director | Verona Pharma Plc (VRNA) | 07-Aug-24 | Grant | 800,000 | -- | -- | 5% 15.77M to 16.57M | |
09-Aug-24 7:11 PM View: | Hahn Mark W Chief Financial Officer | Verona Pharma Plc (VRNA) | 07-Aug-24 | Payment of Exercise | 314,800 | $2.62 | $824,776.00 | (2%) 15.65M to 15.34M | |
05-Aug-24 9:28 PM View: | Rickard Kathleen A. Chief Medical Officer | Verona Pharma Plc (VRNA) | 01-Aug-24 | Payment of Exercise | 106,232 | $2.83 | $300,902.00 | (4%) 2.62M to 2.52M | |
05-Aug-24 9:29 PM View: | Zaccardelli David President and CEO Director | Verona Pharma Plc (VRNA) | 01-Aug-24 | Payment of Exercise | 88,544 | $2.83 | $250,801.00 | (< 1%) 15.85M to 15.77M | |
03-May-24 7:21 PM View: | Rickard Kathleen A. Chief Medical Officer | Verona Pharma Plc (VRNA) | 03-May-24 | Sale (Planned) | 36,248 | $1.96 | $71,031.60 | (1%) 2.66M to 2.62M | |
03-May-24 7:23 PM View: | Hahn Mark W Chief Financial Officer | Verona Pharma Plc (VRNA) | 01-May-24 | Payment of Exercise | 88,544 | $1.93 | $171,005.00 | (< 1%) 15.03M to 14.94M | |
03-May-24 7:19 PM View: | Zaccardelli David President and CEO Director | Verona Pharma Plc (VRNA) | 01-May-24 | Payment of Exercise | 88,544 | $1.93 | $171,005.00 | (< 1%) 15.94M to 15.85M | |
03-May-24 7:21 PM View: | Rickard Kathleen A. Chief Medical Officer | Verona Pharma Plc (VRNA) | 01-May-24 | Payment of Exercise | 73,824 | $1.93 | $142,576.00 | (3%) 2.73M to 2.66M | |
05-Feb-24 6:11 PM View: | Rickard Kathleen A. Chief Medical Officer | Verona Pharma Plc (VRNA) | 05-Feb-24 | Sale (Planned) | 36,248 | $2.22 | $80,503.20 | (1%) 2.77M to 2.73M | |
05-Feb-24 6:11 PM View: | Zaccardelli David President and CEO Director | Verona Pharma Plc (VRNA) | 01-Feb-24 | Payment of Exercise | 480,200 | $2.29 | $1,101,480.00 | (3%) 16.42M to 15.94M | |
05-Feb-24 6:10 PM View: | Poll Claire General Counsel | Verona Pharma Plc (VRNA) | 01-Feb-24 | Gift | 116,592 | -- | -- | 4% 2.9M to 3.02M | |
05-Feb-24 6:11 PM View: | Rickard Kathleen A. Chief Medical Officer | Verona Pharma Plc (VRNA) | 01-Feb-24 | Payment of Exercise | 72,768 | $2.29 | $166,915.00 | (3%) 2.84M to 2.77M | |
05-Feb-24 6:10 PM View: | Poll Claire General Counsel | Verona Pharma Plc (VRNA) | 01-Feb-24 | Gift | 116,592 | -- | -- | (4%) 2.92M to 2.8M | |
05-Feb-24 6:10 PM View: | Poll Claire General Counsel | Verona Pharma Plc (VRNA) | 01-Feb-24 | Payment of Exercise | 103,408 | $2.29 | $237,197.00 | (3%) 3.02M to 2.92M | |
05-Feb-24 6:09 PM View: | Hahn Mark W Chief Financial Officer | Verona Pharma Plc (VRNA) | 01-Feb-24 | Payment of Exercise | 480,664 | $2.29 | $1,102,550.00 | (3%) 15.51M to 15.03M | |
22-Nov-23 5:09 PM View: | Edwards Martin Director | Verona Pharma Plc (VRNA) | 20-Nov-23 | Private Purchase | 33,736 | $1.84 | $61,973.00 | 30% 111.06K to 144.8K | |
08-Nov-23 4:15 PM View: | Ebsworth David R Director | Verona Pharma Plc (VRNA) | 06-Nov-23 | Private Purchase | 160,000 | $1.98 | $316,080.00 | 23% 684.64K to 844.64K | |
03-Nov-23 8:11 PM View: | Rickard Kathleen A. Chief Medical Officer | Verona Pharma Plc (VRNA) | 03-Nov-23 | Sale (Planned) | 58,752 | $1.92 | $112,804.00 | (2%) 2.9M to 2.84M | |
03-Nov-23 8:09 PM View: | Poll Claire General Counsel | Verona Pharma Plc (VRNA) | 01-Nov-23 | Gift | 196,096 | -- | -- | 7% 2.88M to 3.08M | |
03-Nov-23 8:09 PM View: | Zaccardelli David President and CEO Director | Verona Pharma Plc (VRNA) | 01-Nov-23 | Payment of Exercise | 809,008 | $1.74 | $1,410,750.00 | (5%) 17.23M to 16.42M | |
03-Nov-23 8:09 PM View: | Poll Claire General Counsel | Verona Pharma Plc (VRNA) | 01-Nov-23 | Gift | 196,096 | -- | -- | (7%) 2.9M to 2.71M | |
03-Nov-23 8:08 PM View: | Hahn Mark W Chief Financial Officer | Verona Pharma Plc (VRNA) | 01-Nov-23 | Payment of Exercise | 809,008 | $1.74 | $1,410,750.00 | (5%) 16.32M to 15.51M | |
03-Nov-23 8:09 PM View: | Poll Claire General Counsel | Verona Pharma Plc (VRNA) | 01-Nov-23 | Payment of Exercise | 173,904 | $1.74 | $303,254.00 | (6%) 3.08M to 2.9M | |
03-Nov-23 8:11 PM View: | Rickard Kathleen A. Chief Medical Officer | Verona Pharma Plc (VRNA) | 01-Nov-23 | Payment of Exercise | 173,136 | $1.74 | $301,915.00 | (6%) 3.07M to 2.9M | |
24-Oct-23 4:05 PM View: | Hahn Mark W Chief Financial Officer | Verona Pharma Plc (VRNA) | 20-Oct-23 | Grant | 800,000 | -- | -- | 5% 15.52M to 16.32M | |
24-Oct-23 4:06 PM View: | Poll Claire General Counsel | Verona Pharma Plc (VRNA) | 20-Oct-23 | Grant | 200,000 | -- | -- | 7% 2.68M to 2.88M | |
24-Oct-23 4:06 PM View: | Rickard Kathleen A. Chief Medical Officer | Verona Pharma Plc (VRNA) | 20-Oct-23 | Grant | 200,000 | -- | -- | 7% 2.87M to 3.07M | |
24-Oct-23 4:06 PM View: | Zaccardelli David President and CEO Director | Verona Pharma Plc (VRNA) | 20-Oct-23 | Grant | 800,000 | -- | -- | 5% 16.43M to 17.23M | |
07-Aug-23 9:15 PM View: | Poll Claire General Counsel | Verona Pharma Plc (VRNA) | 07-Aug-23 | Gift | 89,976 | -- | -- | 3% 2.68M to 2.77M | |
07-Aug-23 9:15 PM View: | Poll Claire General Counsel | Verona Pharma Plc (VRNA) | 07-Aug-23 | Sale (Planned) | 1,512 | $2.47 | $3,731.46 | (< 1%) 2.68M to 2.68M | |
07-Aug-23 9:17 PM View: | Hahn Mark W Chief Financial Officer | Verona Pharma Plc (VRNA) | 07-Aug-23 | Sale (Planned) | 8,616 | $2.47 | $21,263.40 | (< 1%) 15.53M to 15.52M | |
07-Aug-23 9:15 PM View: | Poll Claire General Counsel | Verona Pharma Plc (VRNA) | 07-Aug-23 | Gift | 89,976 | -- | -- | (3%) 2.77M to 2.68M | |
07-Aug-23 9:19 PM View: | Rickard Kathleen A. Chief Medical Officer | Verona Pharma Plc (VRNA) | 07-Aug-23 | Sale (Planned) | 1,600 | $2.47 | $3,948.64 | (< 1%) 2.87M to 2.87M | |
07-Aug-23 9:17 PM View: | Zaccardelli David President and CEO Director | Verona Pharma Plc (VRNA) | 07-Aug-23 | Sale (Planned) | 8,616 | $2.47 | $21,263.40 | (< 1%) 16.44M to 16.43M | |
07-Aug-23 9:15 PM View: | Poll Claire General Counsel | Verona Pharma Plc (VRNA) | 04-Aug-23 | Sale (Planned) | 26,352 | $2.50 | $65,858.90 | (< 1%) 2.71M to 2.68M | |
07-Aug-23 9:17 PM View: | Hahn Mark W Chief Financial Officer | Verona Pharma Plc (VRNA) | 04-Aug-23 | Sale (Planned) | 150,000 | $2.50 | $374,880.00 | (< 1%) 15.68M to 15.53M | |
07-Aug-23 9:19 PM View: | Rickard Kathleen A. Chief Medical Officer | Verona Pharma Plc (VRNA) | 04-Aug-23 | Sale (Planned) | 27,944 | $2.50 | $69,837.60 | (< 1%) 2.9M to 2.87M | |
07-Aug-23 9:17 PM View: | Zaccardelli David President and CEO Director | Verona Pharma Plc (VRNA) | 04-Aug-23 | Sale (Planned) | 150,000 | $2.50 | $374,880.00 | (< 1%) 16.59M to 16.44M |